Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2011

01.01.2011 | Clinical Study – Patient Study

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005

verfasst von: Rafael Fuentes-Raspall, Loreto Vilardell, Ferran Perez-Bueno, Carmen Joly, Maria Garcia-Gil, Adelaida Garcia-Velasco, Rafael Marcos-Gragera

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to describe the incidence and survival of primary Central Nervous System (CNS) malignancies using data from the population-based cancer registry for Girona province (north-east Spain).
We included all cases of primary CNS malignancies registered between 1994 and 2005. Pathological diagnoses were reviewed and grouped according to the 2007 WHO Classification. Meningeal, soft tissue tumours, spinal cord tumours and primary CNS lymphoma were not included. Cases notified only by death certificate were excluded from the survival analysis. Kaplan and Meier survival curves were calculated from date of diagnosis to death or end of study (31 December 2005), as was relative survival. A total of 493 new CNS cancer patients were registered during the study period: 49.3% astrocytic, 3.4% oligodendroglial and oligoastrocytic tumours, 2.6% ependimal tumours, 3.7% embryonal tumours, 0.2% choroid plexus and 41% without histological confirmation. The mean age (in years) for embryonal tumours was 18.17 years, these being the younger patients in the sample, and 66.34 years for those without histological confirmation, the older patients. Overall, the age standardised incidence rate was 5.88 cases/100,000 people/year (men = 6.81; women = 4.99) with an increasing trend by age until the 70–74 age group. Five-year observed survival rates were: 14.6% for astrocytic tumours, 35.7% for oligodendroglial and oligoastrocytic tumours, 41.0% for ependymal tumours, 32.4% for embryonal tumours and 7.5% for those without histological confirmation (log rank test: P < 0.001). Five-year observed survival rates for astrocytic tumours were analyzed separately by tumour grading, with 37% for diffuse astrocytoma, 7.1% for anaplastic astrocytoma and 4.7% for glioblastoma (log rank test: P < 0.001).
Our results show that astrocytic tumours are most frequently diagnosed and glioblastoma patients have the worst survival figures for the area covered by our population cancer registry.
The high observed incidence of histologically unverified tumours is most probably due to easy access to state of the art CNS imaging in our area.
Literatur
1.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
2.
Zurück zum Zitat Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259CrossRefPubMed Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259CrossRefPubMed
3.
Zurück zum Zitat Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMed Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMed
4.
Zurück zum Zitat Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan A (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108:642–648CrossRefPubMed Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan A (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108:642–648CrossRefPubMed
5.
Zurück zum Zitat Chang SM, Parney IF, Huang W, Anderson FA, Asher AL, Bernstein M, Lillehei KO, Brem MS, Berger MS, Laws ER for the Glioma Outcomes Project Investigators (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557–564CrossRefPubMed Chang SM, Parney IF, Huang W, Anderson FA, Asher AL, Bernstein M, Lillehei KO, Brem MS, Berger MS, Laws ER for the Glioma Outcomes Project Investigators (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557–564CrossRefPubMed
6.
Zurück zum Zitat Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, Kruchko C, McCarthy DJ, Rajaraman P, Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels JL, Wrensch M, Buffler PA, Brain Tumor Epidemiology Consortium (2008) Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer 113(7 Suppl):1953–1968CrossRefPubMed Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, Kruchko C, McCarthy DJ, Rajaraman P, Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels JL, Wrensch M, Buffler PA, Brain Tumor Epidemiology Consortium (2008) Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer 113(7 Suppl):1953–1968CrossRefPubMed
7.
Zurück zum Zitat Fleury A, Menegoz F, Grosclaude P, Daures JP, Henry-Amar M, Raverdy N, Schaffer P, Poisson M, Delattre JY (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79:1195–1202CrossRefPubMed Fleury A, Menegoz F, Grosclaude P, Daures JP, Henry-Amar M, Raverdy N, Schaffer P, Poisson M, Delattre JY (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79:1195–1202CrossRefPubMed
8.
Zurück zum Zitat Helseth A, Mork SJ (1989) Neoplasms of the central nervous system in Norway. III. Epidemiological characteristics of intracranial gliomas according to histology. Acta Pathol Microbiol Immunol Scand 97:547–555 Helseth A, Mork SJ (1989) Neoplasms of the central nervous system in Norway. III. Epidemiological characteristics of intracranial gliomas according to histology. Acta Pathol Microbiol Immunol Scand 97:547–555
9.
Zurück zum Zitat Joensen P (1981) Incidence of primary intracranial neoplasms in an isolated population (the Faroese) during the period 1962–1975. Acta Neurol Scand 64:74–78CrossRefPubMed Joensen P (1981) Incidence of primary intracranial neoplasms in an isolated population (the Faroese) during the period 1962–1975. Acta Neurol Scand 64:74–78CrossRefPubMed
10.
Zurück zum Zitat Kallio M (1988) The incidence of intracranial gliomas in southern Finland. Acta Neurol Scand 78:480–483CrossRefPubMed Kallio M (1988) The incidence of intracranial gliomas in southern Finland. Acta Neurol Scand 78:480–483CrossRefPubMed
11.
Zurück zum Zitat Guomundsson KR (1970) A survey of tumours of the central nervous system in Iceland during the 10-year period 1954–1963. Acta Neurol Scand 46:538–552CrossRefPubMed Guomundsson KR (1970) A survey of tumours of the central nervous system in Iceland during the 10-year period 1954–1963. Acta Neurol Scand 46:538–552CrossRefPubMed
12.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumors of the central nervous system. IARC Press, Lyon, France Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumors of the central nervous system. IARC Press, Lyon, France
13.
Zurück zum Zitat Clèries R, Valls J, Esteban L, Gàlvez J, Pareja L, Sanz X, Alliste L, Martinez JM, Moreno V, Bosch X, Borras JM, Ribes JM (2007) WAERS: an application for Web-assisted estimation of relative survival. Med Inform Internet Med 32:169–175CrossRefPubMed Clèries R, Valls J, Esteban L, Gàlvez J, Pareja L, Sanz X, Alliste L, Martinez JM, Moreno V, Bosch X, Borras JM, Ribes JM (2007) WAERS: an application for Web-assisted estimation of relative survival. Med Inform Internet Med 32:169–175CrossRefPubMed
14.
15.
Zurück zum Zitat Elandt-Johnson RC, Johnson NL (1980) Survival models and data analysis. Wiley, New York Elandt-Johnson RC, Johnson NL (1980) Survival models and data analysis. Wiley, New York
16.
Zurück zum Zitat Helseth A, Langmark F, Mork SJ (1988) Neoplasms of the central nervous system in Norway. II. Descriptive epidemiology of intracranial neoplasms 1955–1984. Acta Pathol Microbiol Immunol Scand 96:1066–1074 Helseth A, Langmark F, Mork SJ (1988) Neoplasms of the central nervous system in Norway. II. Descriptive epidemiology of intracranial neoplasms 1955–1984. Acta Pathol Microbiol Immunol Scand 96:1066–1074
17.
Zurück zum Zitat Bailey P, Cushing H (1926) A classification of the tumours of the glioma group on a histogenic basis with a correlated study of prognosis. Lippincott, Philadelphia Bailey P, Cushing H (1926) A classification of the tumours of the glioma group on a histogenic basis with a correlated study of prognosis. Lippincott, Philadelphia
18.
Zurück zum Zitat Kros JM (2007) From expert opinion to evidence-based: changes in the gold standard of primary brain tumour diagnosis. J Pathol 213:1–3CrossRefPubMed Kros JM (2007) From expert opinion to evidence-based: changes in the gold standard of primary brain tumour diagnosis. J Pathol 213:1–3CrossRefPubMed
Metadaten
Titel
Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005
verfasst von
Rafael Fuentes-Raspall
Loreto Vilardell
Ferran Perez-Bueno
Carmen Joly
Maria Garcia-Gil
Adelaida Garcia-Velasco
Rafael Marcos-Gragera
Publikationsdatum
01.01.2011
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2011
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-010-0240-7

Weitere Artikel der Ausgabe 1/2011

Journal of Neuro-Oncology 1/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.